[18F]FDG Uptake in Adipose Tissue Is Not Related to Inflammation in Type 2 Diabetes Mellitus

Reijrink, M., de Boer, S. A., Antunes, I. F., Spoor, D. S., Heerspink, H. J. L., Lodewijk, M. E., Mastik, M. F., Boellaard, R., Greuter, M. J. W., Benjamens, S., Borra, R. J. H., Slart, R. H. J. A., Hillebrands, J-L. & Mulder, D. J., Feb-2021, In : Molecular Imaging and Biology. 23, 1, p. 117-126 10 p.

Research output: Contribution to journal › Article › Academic › peer-review

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF

Jhund, P. S., Solomon, S. D., Docherty, K. F., Heerspink, H. J. L., Anand, I. S., Böhm, M., Chopra, V., de Boer, R. A., Desai, A. S., Ge, J., Kitakaze, M., Merkely, B., O'Meara, E., Schou, M., Tereshchenko, S., Verma, S., Vinh, P. N., Inzucchi, S. E., Køber, L., Kosiborod, M. N. & 7 others, Martinez, F. A., Ponikowski, P., Sabatine, M. S., Bengtsson, O., Langkilde, A. M., Sjöstrand, M. & McMurray, J. J. V., 26-Jan-2021, In : Circulation. 143, 4, p. 298-309 12 p.

Research output: Contribution to journal › Article › Academic › peer-review

Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease

van der Aart-van der Beek, A. B., Koomen, J. V., Dekkers, C. C. J., Barbour, S. J., Boulton, D. W., Gansevoort, R. T., Greasley, P. J., Abdul Gafor, A. H., Laverman, G. D., Li, Q., Lim, S. K., Stevens, J., Vervloet, M. G., Singh, S., Cattran, D. C., Reich, H. N., Cherney, D. Z. I. & Heerspink, H. J. L., 15-Feb-2021, In : Clinical Pharmacokinetics. 9 p.

Research output: Contribution to journal › Article › Academic › peer-review

HDL particle subspecies and their association with incident type 2 diabetes: the PREVEND study

Sokooti, S., Flores-Guerrero, J. L., Kieneker, L. M., Heerspink, H. J. L., Connelly, M. A., Bakker, S. J. L. & Dullaart, R. P. F., 10-Feb-2021, In : Journal of Clinical Endocrinology and Metabolism.

Research output: Contribution to journal › Article › Academic › peer-review

A metabolomics based molecular pathway analysis for how the SGLT2-inhibitor dapagliflozin may slow kidney function decline in patients with diabetes

Mulder, S., Hammarstedt, A., Nagaraj, S. B., Nair, V., Ju, W., Hedberg, J., Greasley, P. J., Eriksson, J. W., Oscarsson, J. & Heerspink, H. J. L., Jul-2020, In : Diabetes obesity & metabolism. 22, 7, p. 1157-1166 10 p.

Research output: Contribution to journal › Article › Academic › peer-review